RED CELL GENOTYPING AND THE FUTURE OF PRE-TRANSFUSION TESTING

David J Anstee

Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol UK.

For correspondence: david.anstee@nhsbt.nhs.uk
Abstract

Over the past 20 years the molecular bases of almost all the major blood group antigens have been determined. This research has enabled development of DNA-based methods for determination of blood group genotype. The most notable application of these DNA-based methods has been for determination of fetal blood group in pregnancies where the fetus is at risk from Hemolytic Disease of the Fetus and Newborn (HDFN). The replacement of all conventional serological methods for pre-transfusion testing by molecular methods is not straightforward. For the majority of transfusion recipients matching beyond ABO and D type is unnecessary and the minority of untransfused patients at risk of alloimmunization who would benefit from more extensively blood group matched blood cannot be identified reliably. Even if a method to identify individuals most likely to make alloantibodies were available this would not of itself guarantee the provision of extensively phenotype matched blood for these patients because this is determined by the size and racial composition of blood donations available for transfusion. However, routine use of DNA-based extended phenotyping to provide optimally matched donations for patients with pre-existing antibodies or patients with a known predisposition to alloimmunization such as those with sickle cell disease, is widely employed.

Introduction

More than 300 inherited blood group antigens have been described on the surface of human red cells (1,2). With rare exceptions these antigens were first revealed by detection of antigen-specific antibodies present in human serum using the agglutination method. Fewer than 50 of these blood group antigens are known to be polymorphic in any region of the world. That is, to have alternate alleles present in a population at levels greater than can be maintained by recurrent mutation (3). Of those antigens that are polymorphic, few stimulate antibodies of clinical significance by causing transfusion reactions or hemolytic disease of the fetus and the newborn (HDFN) (4:Figure 1) Consequently, safe transfusion for the majority of recipients can be assured by the correct typing of patients and donors with respect to ABO phenotype and screening the patients serum for the presence of clinically significant antibodies directed against antigens polymorphic in the local population. In populations where the RhD antigen is polymorphic it is accepted practice to type all donors and recipients for RhD because anti-D will be found commonly and it is a major cause of HDFN and transfusion reactions. In the Far East where the D negative phenotype is uncommon and anti-D rarely seen, this may not be necessary (5). The “type and screen” procedure has the weakness that antibodies to rare non-polymorphic antigens will not be detected (ca.0.06% of cases) but the antibodies missed are rarely of clinical significance (6,7). A further refinement for patients without irregular antibodies is the computer crossmatch provided appropriate safeguards to prevent issue
of ABO-incompatible blood are built into the software (8). Over the past 30 years there has been a trend in Blood Banking towards reducing the amount of pre-transfusion testing and to introduction of modified versions of the agglutination test like the gel test which can be carried out safely by laboratory staff without extensive practical training in traditional serological methods (9). These procedures are perfectly acceptable for most transfusion recipients but more extensive pre-transfusion matching of donor blood for patients with diseases where there is a high risk of alloimmunization (sickle cell anemia, thalassemia) is desirable and has become common practice in many laboratories (10,11). In recent years national hemovigilance procedures have confirmed the efficacy of these serological approaches and the focus for efforts to increase transfusion safety has moved from laboratory methods to the avoidance of errors occurring after blood has left the Blood Bank (12,13).

In parallel with the trend to reduce the amount and complexity of pre-transfusion testing there has been intense research activity directed at the molecular characterization of blood group genes and determination of the molecular basis of blood group polymorphisms (14). The knowledge that has been obtained has opened up the possibility of a new approach to blood group antigen typing based on DNA sequence determination rather than agglutination. DNA-based methods have the fundamental weakness of not detecting directly the presence of an antigen on the surface of a red cell nevertheless there are several clinical situations in which this approach has proved to be a valuable addition to the range of blood grouping methods available. This paper reviews the impact such DNA-based methods have already made on the provision of healthcare in Transfusion and Neonatal Medicine and considers the extent to which they are likely to impact on existing routine laboratory procedures for pre-transfusion testing.

**Blood Group Genes encoding polymorphic antigens commonly stimulating blood group antibodies of clinical significance**

In order to achieve safe red cell transfusions three major blood group requirements must be satisfied. First and most important, the red cells to be transfused must be ABO compatible. Second, RhD positive red cells should not be given to women of phenotype RhD negative. Third, transfused red cells should lack blood group antigens reactive with any pre-existing clinically significant antibodies the recipient may have. Are DNA-based typing methods for ABO, RhD and other antigens giving rise to clinically significant antibodies sufficiently robust to be considered as replacements for existing serological methods of pre-transfusion testing?

**DNA-Based typing for ABO antigens**

The ABO blood group system is the most clinically important blood group system because antibodies against A and/or B antigens are naturally present in the serum of individuals whose red cells express blood group B, A or O. Every student of transfusion medicine quickly learns that ABO incompatible
transfusions are potentially fatal. It follows that universal blood typing using DNA-based methods alone cannot be considered in the absence of a totally robust method for predicting ABO phenotype. The molecular basis of the ABO blood group system was elucidated in 1990 (15). The ABO phenotype of an individual is determined by the expression of a single glycosyltransferase gene on chromosome 9. The 3-dimensional structure of the B-transferase was elucidated by Patanaude et al. (16, figure 2). The antigens A, B and their variants result from functional glycosyltransferase genes capable of transferring N-Acetyl D–Galactosamine and/or D-Galactose to the non-reducing ends of suitable oligosaccharide chains found on red cell membrane glycoproteins and glycolipids. The red cell phenotype denoted O occurs because the glycosyltransferase gene that generates A and/or B antigen is inactive.

The fact that group O results from an inactive gene creates a major and fundamental problem for the design of DNA-based methods for ABO typing because inactivating mutations causing a group O phenotype occur in many different places in the coding region of the ABO gene. The most common O allele (O1) is distinguished from the A1 allele because of a G deletion at codon 261 which creates a frameshift resulting in a truncated translated protein of 117 amino acids lacking an enzyme active site. In contrast, the O2 allele has six SNPs distinguishing it from the A1 allele. The most significant of the SNPs (G802A) results in a Gly268Arg substitution in the active site of the enzyme rendering it inactive (17, figure 2). The O2 allele has a G insertion at 804 resulting in a frameshift and truncated inactive protein of 56 amino acids. The O5 and O6 alleles have nucleotide substitutions C322T and G542A respectively which create stop codons resulting in inactive proteins of 107 and 181 residues. These non-deletional alleles all occur on an A1 allele background so any DNA-based method which is not designed to select all O alleles may erroneously type the sample as A1. Obviously this is a major problem because of the risk of incorrectly typing a recipient as A when they are in fact O and an incompatible transfusion being given. Storry et al (18) describe such a case. A kidney transplant donor typed as A with DNA-based methods but conventional serology showed the donor to be group O with anti-A and Anti-B in their serum. Two recent papers provide a comprehensive discussion of the methodological problems inherent in DNA-based ABO typing particularly with respect to the known O genotypes (19, 20).

Knowledge of the different molecular bases of the group O phenotype in different world populations permits the development of DNA-based assays capable of detecting all known alleles but cannot allow for novel inactivating mutations not yet observed. Consequently, there will always be the possibility of an occasional ABO incompatible transfusion if such methods are used to replace established procedures. One way of minimising risk would be additional testing of all samples for the presence of anti-A and anti-B but even so it is difficult to see how DNA-based methods could be used in the absence of conventional serology to confirm ABO type.
It is almost 20 years since the transcribed products of genes encoding Rh blood group antigens were identified. RHCE was described in 1990 [21,22] and RHD shortly thereafter [23,24,25]. These findings brought to an end 50 years of controversy in which rival groups hypothesised the Rh antigens were either the product of a single RH gene [26] or three closely linked RH genes, C, D, E [27]. It was proposed that the two Rh genes give rise to three polypeptides with the products of RHCE being separate spliceoforms encoding Cc and Ee antigens respectively [28] but when RHCE was expressed in vitro it was clear that one polypeptide (CE polypeptide) could express both Cc and Ee antigens and that two genes RHD and RHCE, encode two polypeptides denoted D and CE polypeptides respectively [29]. Consequently, the two genes/three polypeptides hypothesis has been abandoned. Recently, the 3D-structure of a bacterial analogue of the Rh-associated glycoprotein has been reported (30,31). This structure allows more reliable modeling of the D and CE polypeptides than previously possible (32). Figure 3 depicts models of the structure of D and CE polypeptides with the positions of the numerous amino acid differences identified.

The D antigen is often referred to as the most complex of the blood group antigens. The explanation for this apparent complexity is simple. In peoples of European origin a complete deletion of RHD and hence complete absence of the D polypeptide from the red cell surface is very common. Consequently, anti-D has been defined as an antibody failing to react with red cells lacking D polypeptide. D antigen is therefore quite different from other blood group antigens which result from nucleotide transitions changing a single amino acid in the protein sequence of the appropriate blood group-active protein (see below). It follows that any individual inheriting an RHD with a mutation which changes the protein sequence of the D polypeptide may appear to have an abnormal type of D antigen, particularly if the red cells are tested with a wide variety of monoclonal anti-D’s since those antibodies recognizing the region of the protein containing or affected by the mutation may fail to react with the individual’s red cells. The situation is further complicated by the occurrence of the adjacent and homologous gene RHCE. Gene conversion events between RHD and RHCE at meiosis can create hybrid alleles encoding proteins with sequence derived from both D and CE polypeptides (Figure 4a;14). Following elucidation of the genetic basis of major Rh antigens D, Cc and Ee (figure 3) numerous studies of RHD and RHCE in individuals having weakly expressed or altered D and other Rh blood group antigens have provided a detailed catalogue of genetic variation in these genes in different ethnic groups [14,33]. DNA-based methods are ideally suited to the elucidation of variant Rh antigens and provide a much more powerful tool for this purpose than conventional serology. However, elucidation of the molecular basis of an Rh variant and the frequency with which it occurs in a given population does not reveal the clinical significance of the variant since that is determined by its immunogenicity.

The major clinical problem associated with Rh proteins is HDFN caused by anti-D (for review see [34]). In Western Europe the D negative phenotype
results from a deletion of \textit{RHD} [35]. The cause of the D negative phenotype in the various populations of Central Asia has not been formally determined. However, methods designed to detect the deletion of \textit{RHD} in fetal DNA give reliable results for D negative Asian Indians residing in the United Kingdom suggesting a similar deletion phenotype to that found in Western Europe is present in Central Asia (Finning K personal communication, 2007). A significant proportion of D negative individuals of African origin do not have a complete deletion of \textit{RHD} [36]. In the indigenous peoples of South East Asia the D negative phenotype is rarely encountered and consequently HDFN resulting from anti-D is not a common clinical problem. Yan et al [37] tested 305,572 Chinese of whom 99.53\% were D positive. Because of the very high incidence of D positive in Taiwan, routine D typing of donors and patients was discontinued in 1988 and no increase in the incidence of anti-D resulted [5].

Polyclonal anti-D immunoglobulin (syn. Rh immune globulin) is a well established prophylactic treatment for HDFN [38]. This product has an excellent safety record although a recent report describing a patient with factor XI deficiency who developed an inhibitor antibody to factor XI after receiving Rh immune globulin illustrates that the use of such a product is not entirely risk free [39]. Human monoclonal anti-D would avoid this risk and bring the added value of homogeneity and security of supply but the very high costs of bringing such a product to market have so far delayed its introduction. An alternative approach currently under investigation is the use of immunodominant peptides derived from the D polypeptide sequence to induce tolerance to D antigen in D negative women. Early studies using immunodominant D peptides in humanized HLA-DR15 transgenic mice suggest such an approach is feasible [40].

The most valuable contribution to healthcare arising from characterisation of the genes encoding Rh polypeptides has been the introduction of diagnostic testing to determine whether or not a pregnant D negative female carries a fetus of phenotype D positive or D negative. Initially, testing was carried out on fetal DNA obtained by amniocentesis from D negative mothers who had already given birth to a baby affected by HDFN. Amniocentesis is not without risk to the fetus and so wider application of fetal DNA testing was not a practical option until it was shown that sufficient fetal DNA for testing can be derived from a maternal blood sample [41]. Determination of D phenotype using fetal DNA from maternal plasma of D negative mothers with pre-existing anti-D is now a routine diagnostic procedure in many countries [42]. A logical extension of this work would be to test fetal DNA from maternal blood samples of all pregnant D negative women so that Rh immune globulin is given only to those women carrying a D positive fetus. In this way a significant number of women (ca. 40\% of pregnancies in the UK) would avoid unnecessary exposure to Rh immune globulin. The first steps towards achieving this goal have now been taken with two studies reporting successful application of automated testing systems capable of typing large numbers of ante-natal samples [43,44]. HDFN resulting from Rh antibodies other than anti-D is far less common but fetal DNA typing is no less valuable in these cases. Suitable tests for c and E are available [45].
The case for application of DNA-based methods in typing Rh antigens to aid the management of HDFN is clear. Less clear is the proposed routine use of DNA-based methods for determination of the many variants of D found in blood donors and patients. There is no doubt the technology to do this is available [46,47]. What is yet to be resolved is whether sufficient clinical benefit would be derived from such testing to justify the cost of implementing the methodology [48,49]. The importance of determining whether or not a patient or donor has a D variant is governed by the likelihood of anti-D stimulation and the probability the anti-D produced will be clinically significant. D variant antigens are often subdivided into partial D and weak D although the distinction between these types of D antigen is so vague as to be meaningless (51) A more useful subdivision would be to list D variant antigens known to have stimulated clinically significant antibodies. Few D variant antigens occur with frequencies above 1 or 2 per 1000 anywhere in the world. Taken together with the paucity of reports of alloimunisation or HDFN resulting from D variant antigens a more selective introduction of DNA-based methods for patient testing may be appropriate. One approach would be use of DNA-based methods to identify only those D variants where the variant is known to stimulate antibody in recipients, in populations where the D variant is polymorphic. In people of European origin the DVI variant falls into this category however, it can be detected using conventional serology with two monoclonal anti-D reagents one of which reacts with DVI positive red cells and the other which does not (Figure 4a). D variant antigens are more common in people of African origin and comprise three types denoted DIVa, DAU and weak D type 4 (includes DIIla and DAR;50;Figure 4b). In this context it is interesting to note that the amino acid substitutions associated with DAR are not predicted to be accessible on the outer surface of the red cell (figure 4b) yet individuals homozygous for DAR can make allo anti-D (52) leading one to conclude that subtle changes in the relative positions of external contact residues in DAR positive individuals are sufficient to allow stimulation of anti-D upon exposure to wild type D antigen. Such a conclusion is consistent with the proposal of Chang and Siegel (53) to account for the fact that the footprints of anti-D’s with different epitope specificities are essentially identical. Castilho et al.(54) report the occurrence of D variant antigens DIIla and/or DAR in 8 of 130 patients with sickle cell disease three of whom had made anti-D and suggest there may be a case for including DNA-based assays for these D variants in selected patient groups however the clinical significance of anti-D produced by these and the majority of D variant antigens is unknown.

If gene chips are introduced for donor testing in Blood Centers inclusion of the additional reactions necessary to detect D variants can easily be accommodated. If gene chips are used for routine testing of patients for genetic susceptibility to disease and a full blood group genotype determination is incorporated into the same chips (discussed further below) the whole debate about the cost effectiveness and clinical value of D variant testing will cease because the information will be obtained en passant.
DNA-based typing for other polymorphic antigens commonly giving rise to clinically significant antibodies

The inherent problems associated with attempting to develop robust DNA-based methodologies for ABO and Rh typing do not apply to polymorphic antigens in other blood group systems. Here allelic antigens generally result from single nucleotide transitions changing one amino acid in the blood group-active protein (syn. single nucleotide polymorphisms, SNPs). Almost all the genes encoding polymorphic blood group antigens in blood group systems have been cloned and the SNPs responsible for the polymorphic antigens associated with clinically significant antibodies identified. Computer modeled 3D-structures are available for many of these blood group-active proteins based on the crystal structures of structural homologues. Actual structures are available for Aquaporin 1 which expresses the Colton Blood Group antigens and for the amino terminal domains 1 and 2 of Lutheran glycoprotein. The actual structures of Lu\(^a\) and Lu\(^b\) antigens are shown in figure 5 to illustrate the structure of a blood group antigen defined by a single amino acid substitution and to emphasise the difference between this type of antigen and D antigen (compare figure 3).

K/k; Kpa/Kpb; Js\(^a\)/Js\(^b\)

Antibodies to the Kell antigen (K1) are the most frequently encountered clinically significant alloantibodies after ABO and Rh antibodies in peoples originating from Europe. The gene encoding Kell glycoprotein was cloned in 1991. It is a type II membrane protein with homology to zinc endopeptidases (M13 family). It occurs in the red cell membrane disulfide bonded to the XK protein. A structural model based on the crystal structure of NEP and depicting amino acid changes which are the loci for antigens within the Kell blood group system is provided by Lee et al. Several methods for DNA-based typing of polymorphic antigens in the Kell blood group system have been described (reviewed in 58). However, it cannot be assumed that typing for these SNPs alone will always give a correct interpretation of Kell phenotype. Poole et al. describe a family in which the red cells have weak K1 expression yet type as homozygous K2 at nucleotide 587. In this case a 577>T change converts codon 193 to serine.

Anti-K1 is responsible for severe neonatal anemia in approximately 40% of K1 positive babies of women with anti-K1. The Kell glycoprotein is expressed very early in erythropoiesis suggesting a functional role for Kell glycoprotein additional to endopeptidase activity. A method for determining the presence of DNA encoding K1 in fetal DNA from maternal plasma has been described.

Fya/Fyb

The gene encoding Fy antigens was cloned in 1993 and fully characterized in 1996. It encodes a seven membrane spanning protein with the Fya/Fyb polymorphism defined by a nucleotide transition giving
Gly (Fya) or Asp (Fyb) at position 42 in the extracellular amino-terminal domain (65). The widespread occurrence of the red cell phenotype Fy(a-b-) in populations deriving from areas where the malarial parasite *Plasmodium vivax* is endemic necessitates the concomitant assay of DNA for a nucleotide substitution in the GATA 1 binding site upstream of FY (66) when molecular Fy typing is undertaken. Other SNPs give rise to weak expression of Fy antigens (Fy<sup>x</sup> reviewed in 67).

Jk<sup>a</sup>/Jk<sup>b</sup>

The gene encoding Jk antigens was cloned in 1994 (68) and the molecular basis of the Jk<sup>a</sup>/Jk<sup>b</sup> polymorphism elucidated in 1997. (69). The gene encodes a urea transporter (HUT 11) predicted to have 10 membrane spanning domains. The Jk<sup>a</sup>/Jk<sup>b</sup> polymorphism results from a SNP (838G>A) which changes Asp280(Jk<sup>a</sup>) to Asn(Jk<sup>b</sup>) in the fourth predicted extracellular loop. Some alleles giving rise to the Jk(a-b-) phenotype may be polymorphic in Asia (particularly Polynesia) and Finland necessitating the determination of additional SNPs for accurate phenotype prediction (70).

Di<sup>a</sup>/Di<sup>b</sup>

The gene encoding Di antigens is the anion exchange protein gene AE1 (syn. band 3). A nucleotide transition (C2561T) changes Leu 854(Di<sup>a</sup>) to Pro 854 (Di<sup>b</sup>) (71). Di<sup>a</sup> is rarely found in peoples of European or African origin but is polymorphic in many of the indigenous peoples of Asia and of North, Central and Southern America.

Do<sup>a</sup>/Do<sup>b</sup>

The Dombrock blood group glycoprotein is a member of the ADP-ribosyltransferase gene family. The polymorphic antigens Do<sup>a</sup> and Do<sup>b</sup> result from a nucleotide transition (A793G) which converts Asn265(Do<sup>a</sup>) to Asp(Do<sup>b</sup>). (72)

Co<sup>a</sup>/Co<sup>b</sup>

The Colton blood group antigens are located on the water transporter, aquaporin 1 (AQP1). The polymorphic antigens Co<sup>a</sup> and Co<sup>b</sup> result from a nucleotide transition (C134T) which converts Ala45(Co<sup>a</sup>) to Val(Co<sup>b</sup>) on the first extracellular loop (55).

S/s

The S/s polymorphism is carried on Glycophorin B Met29(S) or Thr29(s)(73,74). However, DNA-based typing for S/s is problematical in African populations because of the high frequency of the S-s- phenotype which can result from several genetic mechanisms including deletion of GYPB (75).
Applications of red cell genotyping in Transfusion practice

There are several well established and useful applications of DNA-based typing in Transfusion and Neonatal Medicine (reviewed in 76,77; summarized in Table 1). Fetal DNA typing has been used widely for more than a decade and is of proven utility in the management of HDFN (discussed above).

Other applications of DNA-based methods include determining the red cell genotype of patients who have received a large transfusion or have autoimmune hemolytic anemia where conventional serology is not a reliable method of determining the patients blood group.

Extensive screening in order to identify donors with rare blood groups or to establish the frequency of blood group polymorphisms in a given population are useful applications which may be achieved with a high throughput automated system (74,78).

However, there are significant problems precluding any thought of replacing all serological procedures for blood typing with DNA-based methods (see above). In addition to the fundamental problem posed by determination of the group O phenotype, the genes encoding some common non-polymorphic antigens (Vε1;Jra;Ata;MAM;AnWj) which occasionally give rise to clinically significant antibodies have not been cloned and characterized so it is not possible to use molecular methods to detect the absence of these antigens and so identify individuals who may have clinically significant antibodies. These antibodies are very rare but can cause severe transfusion reactions and HDFN. Therefore the introduction of DNA-based blood group typing would have to take place alongside conventional ABO typing and antibody screening and not in isolation. Given the simplicity of conventional methods for D typing there would have to be substantial advantages apart from the benefit accruing from identification of some potentially immunogenic D variant antigens, to introducing more costly DNA-based methods into routine procedure.

High throughput automated DNA-based typing would in principle, allow all transfusion recipients to receive the most blood group compatible blood available from Blood Centres. However, the most blood group compatible blood available is unlikely to match the genotype of the patients at more than 3 or 4 blood group loci because of inventory limitations even in countries with Blood Services collecting millions of donations a year. In any case it makes no sense to attempt such a total matching service given that < 10% of transfusion recipients make allo-antibodies with current matching procedures (79,80). Available evidence supports the view that the ability to make alloantibodies to blood group antigens is genetically determined (80). Clearly, there is a need for DNA-based methods capable of identifying those patients most likely to make antibodies in response to transfusion. If such methods were available then it might be feasible to target this small subset of patients (“responders”) so that they receive the most blood group compatible blood available while non-responders receive ABO and D compatible blood in the conventional
way. Higgins and Sloan (80) argue that since patients who have already made an alloantibody are responders and very likely to make further antibodies it would be sensible to make more fully typed units available to these groups which would include sickle cell disease patients and females of childbearing age.

Extensive prophylactic red cell genotyping to select donors for patients who will receive repeated transfusions over a long period is an attractive application of DNA-based blood grouping. This is particularly relevant to patients with Sickle Cell Disease where the rate of alloimmunization is high (81). A recent survey of 1182 North American laboratories revealed that most laboratories (n=743) typed sickle cell patients for ABO and D only. Most laboratories which performed more extensive phenotyping (n=330) typed for C,E and K (82). Prophylactic matching for Sickle Cell Disease patients using DNA-based methods does not necessarily require the use of extensive DNA arrays (gene chips) and in principle, could be carried out in the Blood Bank using a combination of conventional serology (for ABO and Rh typing) and a DNA-based method utilizing beads or microspheres for other blood group antigens (83, Figure 6). However, this application of red cell genotyping also has limitations. Castro et al (84) in a study of 137 alloimmunized sickle cell patients noted that using limited phenotype matching (for Cc,Ee,K in addition to ABO and D) all alloantibodies would have been prevented for more than half (53.3%) of the patients. If the phenotyping had been extended to include S,Fy\textsuperscript{a} and Jk\textsuperscript{b} all antibodies would have been prevented in 70.8% of patients but whereas 13.6% random white blood donors would match the limited phenotype only 0.6% would match the extended phenotype. By combining recruitment of African American donors and screening for those with the Fy(a-) phenotype using monoclonal anti-Fy3, 12% of donors were extended phenotype matches for 41 sickle cell patients (85). Olujohungbe et al (86) report a much higher incidence of alloimmunization in sickle cell patients in the UK (76% of those transfused) compared with a comparable group in Jamaica (2.6% of those transfused) further emphasising the consequences of disparity between donor and recipient populations. Clearly, the usefulness of DNA-based methods of blood typing to reduce alloimmunization in sickle cell donors is limited by the availability of compatible blood donations.

Assimilation of red cell genotyping into routine practice

As discussed above, optimal use of red cell genotyping in routine practice requires that those patients likely to make alloantibodies can be distinguished from those that are unlikely to make antibodies. At the present time this distinction cannot be made and so the best available option is to utilize DNA-typed donors for patients who have pre-existing antibodies and are therefore known responders and those patients most likely to make alloantibodies like sickle cell disease patients. One possible scenario for the assimilation of DNA-based typing into pre-transfusion testing protocols is depicted in Figure 7a. In this scenario the patients sample is ABO and D typed and screened for antibodies using conventional methods. If antibody is detected and identified, patients DNA is typed by Blood Bank or Blood Centre personnel for other blood groups using a method similar to that depicted in
figure 6. The Blood Centre database of available DNA-typed donors is then searched electronically to find the best match. At Blood Centers with large numbers of donations automated typing of donated blood for multiple blood group loci would most likely be carried out using DNA-arrays or gene chips.

Another scenario is possible if the use of DNA-arrays for genetic screening to establish susceptibility to common diseases becomes part of routine practice in Pathology Laboratories. In this case it would be feasible to include the necessary additional reactions to blood group the patient on the same gene chip. Blood Bank personnel would confirm the patients ABO and D type and perform an antibody screen. If the antibody screen was positive and the antibodies identified or responder status determined, interrogation of the Blood Center database of available donors could proceed directly because DNA-based typing has already been performed. (Figure 7b).

Conclusions

DNA-based blood group typing provides a valuable adjunct not an alternative to traditional methods of pre-transfusion testing. Traditional methods for ABO and D typing are likely to continue and methods for antibody detection and identification will still be required. Theoretically, it is possible to match patient and donor blood group genotypes electronically using gene chip technology. However, this assumes DNA-based methods are totally robust which they are not because novel mutations arise continually. It also assumes the blood available for transfusion at any given time will match all patients blood group phenotypes for all possible polymorphic antigens capable of stimulating clinically significant antibodies which is unrealistic. Tandem application of DNA-based methodology and existing methods will however provide improvements in the provision of extensively blood group phenotyped red cells for patients with alloantibodies.

Acknowledgements

The author thanks Nick Burton for preparing figures 3, 4 and 5, Ed Anstee for preparing figure 1, Martin Olsson for figure 2 and Geoff Daniels and Joyce Poole for critical reading of the manuscript. The authors’ work is funded by the Department of Health (England). DJA wrote the paper; he has no conflicts of interest to declare.

References


6. Oberman HA, Barnes BA, Friedman BA. The risk of abbreviating the major crossmatch in urgent or massive transfusion. Transfusion. 1978; 18:137


45. Finning K, Martin P, Summers J et al. Fetal genotyping for the K(Kell) and Rh C.c and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion. 2007;47:2126-33.


48. Anstee DJ. Goodbye to agglutination and all that? Transfusion. 2005;45;652-3.


56. Mankelow TJ, Burton N, Stefansdottir FO et al.
The Laminin 511/521-binding site on the Lutheran blood group glycoprotein is located at the flexible junction of Ig domains 2 and 3. Blood. 2007 Nov 1;110(9):3398-406. Epub 2007 Jul 17.


58. Lee S. The value of DNA analysis for antigens of the Kell and Kx blood group systems. Transfusion. 2007; 47:(Suppl) 32S-39S.


70. Lomas-Francis C. The value of DNA analysis for antigens of the Kidd blood group system. Transfusion 2007;47(Suppl):23S-27S.


81. Castilho L, Rios M, Bianco C et al. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion.2002;232-238.


83. Karpasitou K, Drago F, Crespiatico L et al. Blood group genotyping for Jk(a)/Jk(b), Fy(a)/Fy(b), S/s,K/k, Kp(a)/Kp(b), Js(a)/Js(b), Co(a)/Co(b), and Lu(a)/Lu(b) with microarray beads. Transfusion 2008;48(3):505-12.

84. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion.2002; 42: 684-90


Table 1

**Useful Applications of Red Cell Genotyping in Transfusion Medicine**

- Fetal DNA typing.
- Extensive blood group typing of donors for alloimmunized patients.
- Determination of the Blood Group of a recently transfused patient.
- Screening blood donors to find rare blood group phenotypes.
- Determining the frequency of blood group polymorphisms in a population.
- RHD zygosity determination for fathers of fetuses at risk of HDFN.
- Blood group typing of patients with autoimmune hemolytic anemia,
Legends to Figures.

Figure 1. Clinical Importance of Antibodies to Blood Group Antigens.

The blood groups systems are given on the abscissa and the number of antigens in each system indicated on the ordinate. Blood group systems containing antigens which often stimulate clinically significant antibodies are shown in red. Blood group systems with antigens which occasionally stimulate clinically significant antibodies are yellow and blood group systems with antigens which rarely if ever stimulate clinically significant antibodies are green.

Figure 2. Structure of the ABO glycosyltransferase.

Amino acid residues differing between blood group A and B-active transferases respectively (Arg176Gly;Gly235Ser;Leu266Met;Gly268Ala) are shown using the single letter code and their positions indicated. The three-dimensional model was created with the DeepView Swiss Pdb Viewer version 3.7.

Figure 3. Models of the Structure of Rh Proteins (32)

(a). Hypothetical heterotrimer comprising RhAG (pink), RhD polypeptide (grey) and RhCE polypeptide (cyan). Residues in the D polypeptide differing from those in the CE polypeptide are shown as blue spheres. Cc and Ee associated residues on the CE polypeptide are shown as red and green spheres respectively.

b. Hypothetical heterotrimer comprising RhAG (pink), Rh D polypeptide (grey) and Rh CE polypeptide (cyan) same as in (a) but showing the molecular surface.

Figure 4. Models of the Structure of D antigen variants DVI type I and DAR

(a) DVI type I polypeptide. Residues encoded by exons 4 and 5 (which are replaced by CE sequence in DVI type I) are shown in cyan. Residues in exons 4 and 5 which differ from those in normal D polypeptide are shown as blue spheres.

(b) DAR polypeptide. Residues which distinguish DAR from normal D polypeptide are shown as red spheres. In this model DAR –associated residues are not surface exposed and not visible on the molecular surface.
Figure 5. Structure of the Lu^a and Lu^b blood group antigens.

Crystal structure of the amino-terminal domain of the Lutheran glycoprotein from Mankelow et al (56) depicting the nucleotide transition (SNP) giving rise to His77 (Lu^a) or Arg77 (Lu^b).

Figure 6. Red Cell genotyping-Blood Group SNPs.

Outline of a method for the determination of blood group SNPs based on that of Karpasitou et al. (83). Many other methods are available (see also 74,77,78). This one is illustrated because it is suitable for “in house” development.

Figure 7. Assimilation of red cell genotyping into routine practice.

(a). Depicts one scenario for incorporating red cell genotyping into routine practice based on technology currently available. It is also possible DNA-based testing could be undertaken at the Blood Bank or another laboratory

(b). Depicts one possible future scenario assuming genetic screening with DNA arrays to identify disease susceptibility will become routine and a genetic test capable of identifying those patients (responders) likely to make alloantibodies to blood group antigens will be available.
Figure 3
Figure 5
Red Cell Genotyping for Blood Group SNPs

Patients gDNA + biotinylated primers

PCR

Denature and hybridize to capture probes covalently coupled to beads

Recover beads and add fluorescent-labelled streptavidin

Detection and analysis of fluorescence emission

Figure 6
Figure 7

A

Blood Bank

Patients Blood Sample

ABO & D type Antibody Screen

Antibody Screen negative

ABO & D Compatible blood issued

Antibody Screen positive

Blood Center

DNA-based typing of patient and Antibody identification

Screen Donor DNA-typed panel

Most compatible blood available issued
Red cell genotyping and the future of pre-transfusion testing

David J Anstee